of the $500 million how much was for lb which doesn't look good right now. as for cash flow he stated his goal was to be cash flow neutral by q4, 2017, hiw words; In early January, we announced our goal of becoming operating cash flow neutral by the end of 2017. as for debt, cfo said we are considering various alternatives. overall looking very bleak right now.
My e-mail was responded to by Carolyn Beaver.
Paul Goodson no longer with Sequenom.
they stated their results are comparable to others so why invest.
sent this to IR, Paul Goodson with no response yet.Paul, Sequenom should negotiate and extend the full debt by 3 full years. Dirk projected revenue of $500 million in 2020. That should be sufficient to retire the debt resulting in a win for both the debt holders and Sequenom. The debt holders do have leverage in so far as they could force a liquidation of Sequenom and its assets. That would only yield pennies on the dollar, a loss for both the debt holders and Sequenom. Sounds like a very good plan to me . What does Sequenom think?
Dr. Ehrich is Sr. Vice President and Chief Scientific Officer at Sequenom, Inc. He joined Sequenom in 2001 in the company’s Hamburg offices and subsequently served in various scientific and management roles within the Sequenom R&D department. His contributions include the development of a high throughput quantitative DNA methylation analysis method, as well as the development of the first-of-its-kind noninvasive prenatal test for fetal chromosomal abnormalities
ene-sequencing giant Illumina (ILMN) was sliding on the stock market Tuesday after Morgan Stanley downgraded it based on negative trends in key markets.
Analyst Steve Beuchaw cut his rating to underweight and lowered his price target to 110 from 130 on Illumina stock. He also lowered his valuation of the cancer franchise to $3.8 billion from $4.9 billion, citing reimbursement pressure from Medicare and Medicaid, as well of the rise of immunotherapies for cancer that don't require genetic testing.
Beuchaw also described a trend in the academic research channel to outsource genome sequencing to centralized labs, reducing the need for locally installed machines. He added, however, that this wasn't a negative call on the entire genomics space.
"We remain positive on share gainers in emerging categories in genomics, notably Natera (NTRA) and NanoString (NSTG) where markets are in their earlier stages of development," he wrote in his downgrade note. "Qiagen (QGEN) is an emerging player in sequencing hardware, and expectations are likely too low for the GeneReader."
Beuchaw added that recovery in the genomics market seemed to be tied to microarrays, which is positive for Thermo Fisher Scientific (TMO) and Agilent (A).
Dirk, our CEO stated that a SCOTUS denial would have no adverse impact on business, this maybe true. On the other hand the PPS is down over 20% since then and 46% YTD and while I'm at it 63% since he was named CEO last September. Number's never lie!